Related references
Note: Only part of the references are listed.Prevalence of drug resistance mutations in HIV-infected individuals with low-level viraemia under combination antiretroviral therapy: an observational study in a tertiary hospital in Northern Taiwan, 2017-19
Shu-Wei Kao et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance
Nokuzola Mbhele et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)
HIV drug resistance among adults initiating antiretroviral therapy in Uganda
Christine Watera et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis
Ke Zhang et al.
FRONTIERS IN PHARMACOLOGY (2021)
Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance
Philip L. Tzou et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2020 Recommendations of the International Antiviral Society-USA Panel
Michael S. Saag et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China
Zhenyan Wang et al.
BMC INFECTIOUS DISEASES (2019)
Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan
Ya-Wei Weng et al.
BMC INFECTIOUS DISEASES (2019)
Surveillance of transmitted HIV drug resistance among newly diagnosed, treatment-naive individuals at a county HIV clinic in Santa Clara County
William Chan et al.
HELIYON (2019)
Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States
Lisa L. Ross et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2018)
HIV-1 integrase strand-transfer inhibitor resistance in southern Taiwan
Hung-Chin Tsai et al.
Oncotarget (2018)
Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naive human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting A retrospective cohort study
Karen Jacobson et al.
MEDICINE (2018)
Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom
A. Tostevin et al.
HIV MEDICINE (2017)
Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection
J. Ambrosioni et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen
Francois Raffi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide
Nicolas A. Margot et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015
Lilian Bulage et al.
BMC INFECTIOUS DISEASES (2017)
Transmitted drug resistance of HIV-1 strains among individuals attending voluntary counselling and testing in Taiwan
Chung-Chih Lai et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships
Andrew Mujugira et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2016)
Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study
Alexandra U. Scherrer et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Prevalence and associated factors for HIV-1 transmitted drug resistance in voluntary clients for counseling and testing in Southern Taiwan
Ya-Wei Weng et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2016)
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
M. S. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Rapid HIV Viral Load Suppression in those Initiating Antiretroviral Therapy at First Visit after HIV Diagnosis
Martin Hoenigl et al.
SCIENTIFIC REPORTS (2016)
Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan
Sui-Yuan Chang et al.
SCIENTIFIC REPORTS (2016)
Disparities in achieving and sustaining viral suppression among a large cohort of HIV-infected persons in care - Washington, DC
Amanda D. Castel et al.
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV (2016)
Psychiatric Distress, Drug Use, and HIV Viral Load Suppression in Russia
A. Ustinov et al.
AIDS AND BEHAVIOR (2016)
Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status
Julia L. Marcus et al.
AIDS PATIENT CARE AND STDS (2015)
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
Jens D. Lundgren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Impact of Drug Resistance-Associated Amino Acid Changes in HIV-1 Subtype C on Susceptibility to Newer Nonnucleoside Reverse Transcriptase Inhibitors
Adriaan E. Basson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis
Quang D. Pham et al.
AIDS (2014)
Resistance to HIV Integrase Strand Transfer Inhibitors Among Clinical Specimens in the United States, 2009-2012
Christopher B. Hurt et al.
CLINICAL INFECTIOUS DISEASES (2014)
Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing
George L. Melikian et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Patients Infected with CRF07_BC Have Significantly Lower Viral Loads than Patients with HIV-1 Subtype B: Mechanism and Impact on Disease Progression
Szu-Wei Huang et al.
PLOS ONE (2014)
Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001-2009
David B. Hanna et al.
CLINICAL INFECTIOUS DISEASES (2013)
Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials
C. Stephan et al.
HIV MEDICINE (2013)
Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection
Sharon L. Walmsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment-Naive Individuals Starting Modern Therapy Combinations
Viktor von Wyl et al.
CLINICAL INFECTIOUS DISEASES (2012)
Patterns of Adherence to Raltegravir-Based Regimens and the Risk of Virological Failure Among HIV-Infected Patients: The RALTECAPS Cohort Study
Guillaume Gras et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan
Chung-Chih Lai et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
Paul E. Sax et al.
LANCET (2012)
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study
Linda Wittkop et al.
LANCET INFECTIOUS DISEASES (2011)
HIV-1 Drug Resistance Mutations Are Present in Six Percent of Persons Initiating Antiretroviral Therapy in Lusaka, Zambia
Raph L. Hamers et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations
Elizabeth C. Reuman et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe
Jurgen Vercauteren et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Jeffrey L. Lennox et al.
LANCET (2009)
The prevalence of transmitted antiretroviral drug resistance in treatment-naive patients and factors influencing first-line treatment regimen selection
H-Y Huang et al.
HIV MEDICINE (2008)
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination Antiretroviral therapy in the EuroSIDA study
Wendy P. Bannister et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
Minority Human Immunodeficiency Virus Type 1 Variants in Antiretroviral-Naive Persons with Reverse Transcriptase Codon 215 Revertant Mutations
Yumi Mitsuya et al.
JOURNAL OF VIROLOGY (2008)
Transmission of HIV-1 drug resistance in Switzerland:: a 10-year molecular epidemiology survey
Sabine Yerly et al.
AIDS (2007)
Prevalence of Antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: Implications for routine resistance screening before initiation of antiretroviral therapy
RM Novak et al.
CLINICAL INFECTIOUS DISEASES (2005)
Human immunodeficiency virus reverse transcriptase and protease sequence database
SY Rhee et al.
NUCLEIC ACIDS RESEARCH (2003)
Coinfection with hepatitis viruses and outcome of initial Antiretroviral regimens in previously naive HIV-Infected subjects
A De Luca et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:: a collaborative analysis of prospective studies
M Egger et al.
LANCET (2002)
Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy
LT Bacheler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
